Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APL-3007 + APL-2
- Development stage
- Unknown
- Lead developer
- Apellis Pharmaceuticals
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Peptides, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravitreal, Subcutaneous
01
Overview
**APL-3007 + APL-2** is an investigational co-administration regimen from Apellis for **geographic atrophy secondary to age-related macular degeneration**. It combines subcutaneous APL-3007, a small interfering RNA designed to reduce production of complement component 3, with intravitreal pegcetacoplan, the C3-targeting cyclic peptide marketed as SYFOVRE and previously known as APL-2. The regimen is intended to provide more comprehensive inhibition of complement activity affecting the retina and choroid. It is being evaluated in a randomized, placebo-controlled Phase 2 study.
- Brand names
- SYFOVRE
- Other names
- APL-3007 + pegcetacoplanAPL-3007 + SYFOVREpegcetacoplan + APL-3007SYFOVRE + APL-3007
02
Targets
C3
Beyond the preview
Go deeper on APL-3007 + APL-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APL-3007 + APL-2.